Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but ...

Recursion strengthened its tech stack through partnerships and collaborations with big players. Read why I will remain on the sidelines of RXRX stock.

Recursion CEO Chris Gibson, PhD, predicts AI will cut drug discovery costs and discusses his company's collaboration with Nvidia.

Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.